Editorial
Is This Clinical Trial Fully Registered? — A Statement from the International Committee of Medical Journal Editors
N Engl J Med 2005; 352:2436-2438June 9, 2005
- Article
In September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a joint editorial aimed at promoting registration of all clinical trials.1 We stated that we will consider a trial for publication only if it has been registered before the enrollment of the first patient. This policy applies to trials that start recruiting on or after July 1, 2005. Because many ongoing trials were not registered at inception, we will consider for publication ongoing trials that are registered before September 13, 2005. Our goal then and now is to foster a comprehensive, publicly available database of clinical trials. A complete registry of trials would be a fitting way to thank the thousands of participants who have placed themselves at risk by volunteering for clinical trials. They deserve to know that the information that accrues from their altruism is part of the public record, where it is available to guide decisions about patient care, and deserve to know that decisions about their care rest on all of the evidence, not just the trials that authors decided to report and that journal editors decided to publish.
We are not alone in pursuing this goal. The World Health Organization (WHO), through meetings in New York, Mexico City, and Geneva, has brought us close to the goal of a single worldwide standard for the information that trial authors must disclose. Around the world, governments are beginning to legislate mandatory disclosure of all trials. For example, among the bodies considering new legislation is the U.S. Congress, where the proposed Fair Access to Clinical Trials (FACT) Act would expand the current mandate for registration of clinical trials. Many other journals have adopted our policy of requiring trial registration. These initiatives show that trial registration has become a public issue. But, as our deadline for registration approaches, trial authors and sponsors want to be sure that they understand our requirements, so that reports of their research will be eligible for editorial review. The purpose of this joint and simultaneously published editorial is to answer questions about the ICMJE initiative and to bring our position into harmony with that of others who are working toward the same end.
Our definition of a clinical trial remains essentially the same as in our September 2004 editorial: “Any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome.” By “medical intervention” we mean any intervention used to modify a health outcome. This definition includes drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. We update our 2004 editorial to state that a trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration.
Among the trials that meet this definition, which need to be registered? The ICMJE wants to ensure public access to all “clinically directive” trials — trials that test a clinical hypothesis about health outcomes (e.g., “Is drug X as effective as drug Y in treating heart failure?”). We have excluded trials from our registration requirement if their primary goal is to assess major unknown toxicity or determine pharmacokinetics (phase 1 trials). In contrast, we think the public deserves to know about trials that could shape the body of evidence about clinical effectiveness or adverse effects. Therefore, we require registration of all trials whose primary purpose is to affect clinical practice (phase 3 trials). Between these two extremes are some clinical trials whose prespecified goal is to investigate the biology of disease or to provide preliminary data that may lead to larger, clinically directive trials.
We recognize that requiring public registration of trials whose prespecified goal is to investigate the biology of disease or to direct further research might slow the forces that drive innovation. Therefore, each journal editor will decide on a case-by-case basis about reviewing unregistered trials in this category. Authors whose trial is unregistered will have to convince the editor that they had a sound rationale when they decided not to register their trial. The ICMJE will maintain this policy for the next two years. We will then review our experience.
Our September 2004 editorial specified the information that we would require for trial registration. Attendees at a recent meeting of the WHO registration advisory group identified a minimal registration data set of 20 items (Table 1Table 1
Minimal Registration Data Set.). The WHO-mandated items collectively address every key requirement that we established in our September 2004 editorial. The ICMJE supports the WHO minimal data set and has adopted it as the ICMJE's requirement: we will consider a trial for publication if the authors register it at inception by completing all 20 fields in the WHO minimal data set. As individual editors, we will review the data in the registration fields when we decide whether to consider the trial for publication. We will consider a registration data set inadequate if it has missing fields or fields that contain uninformative terminology. If an investigator has already registered a clinical trial in a publicly owned, publicly accessible registry using the data fields that we specified in our 2004 editorial, we will consider that registration to be complete as long as each field contains useful information.Acceptable completion of data fields is an important concern. It shouldn't be, but it is. Many entries in the publicly accessible clinicaltrials.gov database do not provide meaningful information in some key data fields. A search conducted on May 4, 2005 (Zarin D.: personal communication) indicates that certain pharmaceutical-company entries list a meaningless phrase (e.g., “investigational drug”) in place of the actual name of the drug, even though a U.S. law requires trial registrants to provide “intervention name” (www.fda.gov/cder/guidance/4856fnl.htm). Many companies and other entities are completing the data fields in a meaningful fashion. Data entries must include information that will be of value to patients and health professionals; the intervention name is needed if one is to search on that intervention.
We recognize that clinical trial registries have many uses, but whatever the use, a worldwide uniform standard for a minimal database is necessary. We have participated in the WHO effort to establish a clinically meaningful trial registration process. The ICMJE supports this ongoing project. When it is complete we will evaluate the process, and if it meets our primary objectives, we will adopt it.
We stated our requirements for an acceptable trial registry in the September 2004 editorial, and they remain the same. The registry must be electronically searchable and accessible to the public at no charge. It must be open to all registrants and not for profit. It must have a mechanism to ensure the validity of the registration data.
The purpose of a clinical trials registry is to promote the public good by ensuring that everyone can find key information about every clinical trial whose principal aim is to shape medical decision-making. We will do what we can to help reach this goal. We urge all parties to register new and ongoing clinical trials. If in doubt about whether a trial is “clinically directive,” register it. Don't use meaningless phrases to describe key information. Every trial participant and every investigator should be asking, “Is this clinical trial fully registered?”
Source Information
Editor-in-Chief, JAMA
Editor-in-Chief, New England Journal of Medicine
Editor, The New Zealand Medical Journal
Editor-in-Chief, Norwegian Medical Journal
Editor, CMAJ
Editor, The Lancet
Executive Editor, MEDLINE, National Library of Medicine
Senior Deputy Editor, Annals of Internal Medicine
Editor, Croatian Medical Journal
Executive Editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)
Editor, Journal of the Danish Medical Association
Editor, Annals of Internal Medicine
Editor, The Medical Journal of Australia
- References
References
1
De Angelis C ,Drazen JM ,Frizelle FA , et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1251
Full Text | Web of Science | Medline
- Citing Articles (39)
Citing Articles
1
Olaf M. Dekkers, Darius Soonawala, Jan P. Vandenbroucke, Matthias Egger. (2011) Reporting of noninferiority trials was incomplete in trial registries. Journal of Clinical Epidemiology 64:9, 1034-1038
CrossRef2
R L Krall. (2011) State of the Controlled Clinical Trial Enterprise in the United States. Clinical Pharmacology & Therapeutics 89:2, 225-228
CrossRef3
B. Seruga, P. C. Hertz, L. W. Le, I. F. Tannock. (2010) Global drug development in cancer: a cross-sectional study of clinical trial registries. Annals of Oncology 21:4, 895-900
CrossRef4
Elodie Pambrun, Vincent Bouteloup, Rodolphe Thiébaut, Julien Asselineau, Victor de Lédinghen, Paul Perez. (2010) On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too. Journal of Clinical Epidemiology 63:3, 342-343
CrossRef5
Annalee Yassi, Shafik Dharamsi, Jerry Spiegel, Alejandro Rojas, Elizabeth Dean, Robert Woollard. (2010) The Good, the Bad, and the Ugly of Partnered Research: Revisiting the Sequestration Thesis and the Role of Universities in Promoting Social Justice. International Journal of Health Services 40:3, 485-505
CrossRef6
W. L. Lanier. (2009) Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?. Mayo Clinic Proceedings 84:9, 771-775
CrossRef7
Udaya K Ranawaka, Colvin Goonaratna. (2009) Establishing the Sri Lanka Clinical Trials Registry. Journal of Evidence-Based Medicine 2:1, 29-31
CrossRef8
Masoud Solaymani-Dodaran, Afshin Ostovar, Davood Khalili, Muhammad Vasei. (2009) Iranian Registry of Clinical Trials: path and challenges from conception to a World Health Organization primary register. Journal of Evidence-Based Medicine 2:1, 32-35
CrossRef9
Benjamin S. Brooke, Hari Nathan, Timothy M. Pawlik. (2009) Trends in the Quality of Highly Cited Surgical Research Over the Past 20 Years. Annals of Surgery 249:1, 162-167
CrossRef10
Theodore Eisenberg, Martin T Wells. (2009) Statins, cholesterol, women and primary prevention: evidence-based medicine or wishful thinking?. Future Cardiology 5:1, 1-4
CrossRef11
Massimo Antonelli, Giovanna Mercurio. (2009) Reporting, access, and transparency: Better infrastructure of clinical trials. Critical Care Medicine 37:Supplement, S178-S183
CrossRef12
Johan P. E. Karlberg. (2008) Trends in disease focus of drug development. Nature Reviews Drug Discovery 7:8, 639-640
CrossRef13
Roger Chou. (2008) Using Evidence in Pain Practice: Part I: Assessing Quality of Systematic Reviews and Clinical Practice Guidelines. Pain Medicine 9:5, 518-530
CrossRef14
A. Vitry, J. Lexchin, L. Sasich, T. Dupin-Spriet, T. Reed, V. Bertele, S. Garattini, L. Toop, E. Hurley. (2008) Provision of information on regulatory authorities websites. Internal Medicine Journal 38:7, 559-567
CrossRef15
Laurence Hirsch. (2008) Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors. Current Medical Research and Opinion 24:6, 1683-1689
CrossRef16
Johan C. F. van Luijn, Pieter Stolk, Frank W. J. Gribnau, Hubert G. M. Leufkens. (2008) Gap in publication of comparative information on new medicines. British Journal of Clinical Pharmacology 65:5, 716-722
CrossRef17
Stefan Gerber, Deborah Tallon, Sven Trelle, Martin Schneider, Peter Jüni, Matthias Egger. (2007) Bibliographic study showed improving methodology of meta-analyses published in leading journals 1993–2002. Journal of Clinical Epidemiology 60:8, 773-780
CrossRef18
David Cohen, David H. Jacobs. (2007) Randomized controlled trials of antidepressants: clinically and scientifically irrelevant. Debates in Neuroscience 1:1, 44-54
CrossRef19
B. C.K. Choi, J. Frank, J. S. Mindell, A. Orlova, V. Lin, A. D.M.G. Vaillancourt, P. Puska, T. Pang, H. A. Skinner, M. Marsh, A. H. Mokdad, S.-Z. Yu, M. C. Lindner, G. Sherman, S. M. Barreto, L. W. Green, L. W. Svenson, P. Sainsbury, Y. Yan, Z.-F. Zhang, J. C. Zevallos, S. C. Ho, L. M. de Salazar. (2007) Vision for a Global Registry of Anticipated Public Health Studies. American Journal of Public Health 97:Supplement 1, S82-S87
CrossRef20
M. Carolina Hinestrosa, Kay Dickersin, Pamela Klein, Musa Mayer, Karin Noss, Dennis Slamon, George Sledge, Frances M. Visco. (2007) Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature Reviews Cancer 7:4, 309-315
CrossRef21
Linda Brubaker. (2007) Clinical trial registration. Neurourology and Urodynamics 26:2, 147-147
CrossRef22
Drazen, Jeffrey M., Zarin, Deborah A., . (2007) Salvation by Registration. New England Journal of Medicine 356:2, 184-185
Full Text23
Jack L. Cronenwett, James M. Seeger. (2007) Requirement for registration of clinical trials. Journal of Vascular Surgery 45:1, 1
CrossRef24
William R. Hendee. (2007) Research with Human Volunteers. Medical Physics 34:7, 3119
CrossRef25
Fernando Alfonso, Javier Segovia, Magda Heras, Javier Bermejo. (2006) Publicación de ensayos clínicos en revistas científicas: consideraciones editoriales. Revista Española de Cardiología 59:11, 1206-1214
CrossRef26
Andrew P. Schachat. (2006) Enhancements. Ophthalmology 113:10, 1694
CrossRef27
Alan Lyles. (2006) The reference case ten years later: Has comparing cost-effectiveness analyses improved?. Clinical Therapeutics 28:8, 1182-1183
CrossRef28
Michael JG Farthing. (2006) Authors and publication practices. Science and Engineering Ethics 12:1, 41-52
CrossRef29
Richard Spaide. (2006) New Treatments for AMD. Ophthalmology 113:1, 160-161
CrossRef30
C. Hanning, P. Rentowl. (2006) A response to 'Living with the European Clinical Trials Directive: one year on'. Anaesthesia 61:1, 78-79
CrossRef31
P KERN. (2006) Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP/ICH). Parasitology International 55, S273-S282
CrossRef32
Haug, Charlotte, Gøtzsche, Peter C., Schroeder, Torben V., . (2005) Registries and Registration of Clinical Trials. New England Journal of Medicine 353:26, 2811-2812
Full Text33
Zarin, Deborah A., Tse, Tony, Ide, Nicholas C., . (2005) Trial Registration at ClinicalTrials.gov between May and October 2005. New England Journal of Medicine 353:26, 2779-2787
Full Text34
Drazen, Jeffrey M., Wood, Alastair J.J., . (2005) Trial Registration Report Card. New England Journal of Medicine 353:26, 2809-2811
Full Text35
Carlos Campillo. (2005) Por un registro único de los ensayos clínicos. El papel de los CEIC y las revistas médicas. Medicina Clínica 125:15, 599
CrossRef36
John H. Stone, Michael D. Lockshin, Patricia P. Katz, Edward H. Yelin. (2005) New journal policy regarding registration of clinical trials. Arthritis & Rheumatism 52:8, 2243-2247
CrossRef37
Philip S. Barie. (2005) Temporary Insanity?. Surgical Infections 6:2, 181-184
CrossRef38
Karmela Krlea-Jerić. (2005) Clinical Trial Registration: The Differing Views of Industry, the WHO, and the Ottawa Group. PLoS Medicine 2:11, e378
CrossRef39
Jesse A. Berlin, Mary C. Wacholtz. (2005) Selective Reporting, Publication Bias and Clinical Trial Registry. International Journal of Pharmaceutical Medicine 19:5-6, 277-284
CrossRef
